It is made available under a CC-BY-NC-ND 4.0 International license .

Risk factors for invasive Group A Streptococcal infection in children aged 6 months to 5 years, a case-control study, the Netherlands, February-May 2023

Elizabeth I Hazelhorst^{1,2}, Catharina E van Ewijk¹, Cornelia CH Wielders¹, Margreet JM te Wierik¹,

Susan JM Hahné¹, Hester E de Melker¹, Mirjam J Knol¹, Brechje de Gier¹

¹ Center for Infectious Disease Control, National Institute for Public Health and the Environment

(RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, the Netherlands

² European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease

Prevention and Control (ECDC), Gustav III:s Boulevard 40, 169 73 Solna, Stockholm, Sweden

It is made available under a CC-BY-NC-ND 4.0 International license .

Summary

In 2022, an increase in invasive Group A Streptococcal infections (iGAS) was observed in the Netherlands. A particular increase was seen among children, therefore we aimed to assess risk factors for iGAS in children aged 6 months to 5 years. A prospective case-control study was conducted between February and May 2023. We approached parents of notified iGAS cases to complete a questionnaire on exposures during 4 weeks prior to disease onset. Controls were recruited via social media and matched to cases (10:1) on sex and birthyear. Conditional logistic regression was performed to estimate odds ratios (OR) of exposures. For the analysis we included 18 cases and 103 controls. Varicella prior to onset of iGAS disease was reported in 2 (11%) cases and 1 (1%) control (OR: 12.0, 95% CI: 1.1-139.0). Exposure to GAS-like illnesses impetigo, pharyngitis and scarlet fever was reported in 8 (44%) cases and 15 (15%) controls (OR: 7.1, 95% CI: 1.8-29.0). Our findings are in line with previous studies by identifying varicella as a risk factor for iGAS among young children and highlight the association with non-invasive GAS infections in the community as a possible source of transmission.

It is made available under a CC-BY-NC-ND 4.0 International license .

Introduction

Group A streptococci (GAS) are gram-positive bacteria (*Streptococcus pyogenes*), which can be carried asymptomatically or cause non-invasive and invasive disease (iGAS). Non-invasive manifestations of GAS include mild diseases such as impetigo and scarlet fever. Invasive infection is rare, and can lead to severe disease such as meningitis or toxic shock syndrome with high case fatality [1]. There is no vaccine available and public health interventions consist mainly of prescribing antibiotic prophylaxis to household contacts of iGAS patients and monitoring of symptoms among close contacts to allow early treatment [2].

In 2022, an increase of iGAS was observed in the Netherlands, especially among children aged 0-5 years. At that time, three manifestations of iGAS were notifiable in the Netherlands: necrotizing fasciitis, streptococcal toxic shock syndrome (STSS) and puerperal fever or -sepsis [2]. In 2022, 42 cases were reported in the age group 0-5 years; a sevenfold increase compared to pre-COVID years 2016-2019 [3]. Of these 42 cases, 9 deceased. The increase in iGAS was also reported by other European countries such as United Kingdom, France and Ireland [4-9]. The increase could not be fully attributed to a specific *emm*-type, even though there is evidence that the proportion of *emm*1 isolates among children aged 0-5 years increased over the year 2022 [3, 10].

Besides the increase in iGAS infections, a rise in primary care consultations was seen in 2022 for pharyngitis, scarlet fever and varicella zoster [3, 10, 11]. Incidences of viral infections such as influenza and varicella, which are known risk factors for iGAS, were higher than in pre-covid years [10-13]. It is also suggested that infection control measures during the COVID-19 pandemic reduced exposure to GAS and other childhood infections, resulting in a decreased immunity and a higher susceptibility for iGAS [14]. This can be a partial explanation of the surge in iGAS cases during winter season 2022-2023. To identify the risk factors for iGAS among children aged 6 months to 5 years in the post-COVID-19 era, we conducted a prospective case-control study in the Netherlands in early 2023.

It is made available under a CC-BY-NC-ND 4.0 International license .

Methods

A prospective case-control study was conducted between 13 February and 30 May 2023 among children aged 6 months to 5 years. A case was defined as a child aged 6 months to 5 years with symptoms of invasive disease and *S. pyogenes* cultured from a normally sterile site or a normally non-sterile site without the presence of another pathogen responsible for the disease, occurring between February and May 2023 in The Netherlands. Parents of all notified cases were invited by the Municipal Health Services (MHS) to participate in the study. If the parents of the case agreed to participate, the online questionnaire was sent by the MHS.

Parents willing to have their children serve as controls were recruited from the general population via social media channels (Facebook, Instagram and LinkedIn) of the National Institute for Public Health and the Environment (RIVM), asking to apply for participation in a survey, which resulted in a pool of potential controls. Controls had to be in the same age range as cases, but without a history of iGAS. In order to take into account the respiratory season, we aimed to have cases and the selected controls filling out the questionnaire around the same moment in time. Whenever a new case was notified, we selected 10 controls from the pool, matched to the case on sex and birthyear, or birth-quarter for children younger than 1 year old. Parents of selected controls were invited via the RIVM by e-mail to fill in the online questionnaire. Controls whose siblings already participated in the study were excluded, as their exposures could not be regarded as independent observations.

The questionnaires' primary exposure of interest was infectious disease during four weeks prior to disease onset (cases) or during the past 4 weeks (controls). Because we were asking parents, and not clinicians, to answer questions about illness, we added clear descriptions of disease presentations such as scarlet fever, impetigo and varicella. For the analysis, the additional variable any GAS-like illness was created. Any GAS-like illness was defined as scarlet fever or impetigo or pharyngitis. We also created the variable respiratory infection, defined as runny nose or cough or shortness of breath or sore throat. Other exposures of interest were household size, chronic illness, use of

4

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316742; this version posted November 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

medication including antibiotics, going to school or daycare, whether a child visited primary care or emergency care unit, admission to hospital, surgical procedures such as tonsillitis, occurrence of infectious diseases in the child's social environment and vaccination against COVID-19 or influenza. As a proxy for social economic status highest education level of one of the parents was asked.

Univariable conditional logistic regression was performed to estimate the odds ratios (OR) and 95% confidence intervals (95% CI) of exposures among iGAS cases and controls to identify risk factors for severe disease. Data cleaning and analyses were done in R version 4.2.2 [15].

We verified whether the work complied with the specific conditions as stated in the Dutch Medical Research Law on Human Subjects (WMO). The research does not fulfill one or both of these conditions. Therefore, the study was exempted for further approval by an ethical research committee. A Data Privacy Impact Assessment (DPIA) was conducted to adhere to the data protection legislation. A digital informed consent of parents of cases and controls was requested before the online questionnaire could be opened.

Results

Of 56 cases notified during the study period, 18 completed the questionnaire (response rate 32%). The control pool existed of 1132 potential controls, of which 578 were matched to a case and therefore invited to fill in the questionnaire. Eighteen additional controls received an invitation erroneously, because of an error in the software used to invite the controls. 351 controls filled in the questionnaire (response rate 61%), with a median of 6 controls per case (interquartile range 4-7). For 248 responding controls, the matched case did not respond, therefore their data could not be included in the primary analysis. An overview of the recruiting process is shown in Figure 1.

For the primary analysis, a total of 18 cases and 103 controls were included. Because of the matching criteria sex and birthyear, the proportions in both groups were similar, see Table 1. Among

It is made available under a CC-BY-NC-ND 4.0 International license .

the cases 10 (56%) were male and 8 (44%) female. Among the controls 55 (53%) were male and 48 (47%) female.

A complete overview of the analyzed variables can be found in Table 2. Prior respiratory infection was reported among 14 (78%) of cases and 87 (85%) controls, this difference was not statistically significant. Likewise, no statistically significant difference was found between cases and controls for impetigo, pharyngitis and scarlet fever. However, when combining these syndromes into the variable GAS-like illness we found a statistically significant difference with an odds ratio of 8.5 (95% CI: 1.5-49.0). Prior varicella zoster infection was reported significantly more among cases (OR: 12.0, 95% CI: 1.1-139.0), as was fever (OR: 7.5, 95% CI: 2.1-28.0). None of the included chronic illnesses were significant risk factors. Other factors such as prior use of antibiotics, household size and attending daycare or school were not significant. Medium or high education level of at least one of the parents was associated with a lower risk of developing iGAS (OR: 0.1, 95% CI: 0.0-0.5).

We also investigated if various infectious disease symptoms were present in the social environment (household, family, friends, daycare or school), of which the GAS-like illnesses had the most significant findings, see Table 3. Three (17%) cases and 1 (1.2%) control reported scarlet fever in their social environment (OR: 24.0, 95% CI: 2.2-257.0). Any GAS like illness was reported in the social environment of 8 (44%) cases and 15 (15%) controls (OR: 7.1, 95% CI: 1.8-29.0). A complete overview of the infectious disease symptoms in the social environment can be found in Supplementary Table 4.

Secondary analysis – varicella zoster

A question about varicella zoster in the 4 weeks prior to disease onset was part of the standard iGAS notification questionnaire. Therefore, this information was available also for cases who did not respond to the questionnaire. We performed a secondary analysis using the data from the notification questionnaire compared to the matched controls. For 47/56 cases, the notification questionnaire contained data about prior varicella zoster infection. A total of 256 control responses

It is made available under a CC-BY-NC-ND 4.0 International license .

were matched to these 47 cases. Prior varicella zoster infection was reported in 6 (13%) cases (2

necrotizing fasciitis, 4 skin and soft tissue infections) and 4 (1.4%) controls (OR: 11.7, 95% CI 3.9-47).

It is made available under a CC-BY-NC-ND 4.0 International license .

Discussion

In this study we aimed to identify risk factors for iGAS infection among young children in early 2023. Our findings are in line with previous studies confirming the association between varicella zoster and iGAS and confirm the association with presence of non-invasive GAS infections in the social environment. This latter association was strongest for scarlet fever.

Varicella zoster is known as risk factor for iGAS, mostly associated with GAS skin and soft tissue infection [11]. In early 2022, with re-opening of society after multiple lockdowns, varicella zoster infections surged after two years of low incidence and a likely build-up of susceptible individuals, in the absence of varicella vaccination in the Netherlands. This provided a likely explanation for the peak in iGAS among young children observed in the Netherlands in early 2022 [3]. After the varicella zoster peak in 2022, 2023 showed a remarkably low varicella zoster incidence [16]. Still, in both our primary and our secondary analysis, we found a strong association between varicella zoster and iGAS infection. Contact with persons with scarlet fever, impetigo or pharyngitis has previously been described as a risk factor for developing iGAS [17, 18]. We found the strongest association between iGAS infection and scarlet fever, the only syndrome in the questionnaire that is specifically caused by GAS infection. Our findings are consistent with the notion that these non-invasive GAS infections can be important sources of transmission [17, 18]. Respiratory viral infections, specifically influenza, have been described previously as a risk factor for iGAS as well [12, 13]. However, in our study there was no statistically significant difference in symptoms of respiratory infection between cases and controls. The interpretation of our finding of fever as a risk factor is difficult, because this may have been an early symptom of the iGAS rather than a prior infection by another pathogen.

A strength of this study is the quick approach of parents of cases via the MHS to fill in the questionnaire which likely minimized recall bias. Also the call for participation of controls via social media was an efficient method to recruit enough controls to conduct the study. Our prospective design, with recruitment of controls at the study onset but sending the questionnaire only when a

8

It is made available under a CC-BY-NC-ND 4.0 International license .

matched case was notified, allowed us to study various seasonal risk factors without confounding by calendar time. This method can be used to quickly deploy case-control studies in future outbreaks where time-varying risk factors are likely to play a role.

One of the main limitations of this study is the low number of included cases. iGAS infection among young children remains a rare disease, and our study commenced almost a year after the start of the iGAS increase in the Netherlands. Also, the majority of the approached parents of cases chose not to participate. Parents of cases were approached during a stressful period when their child was hospitalized, and in some cases deceased. Understandably, many of these parents did not have the mind space for participation. This may also have introduced some selection bias towards cases with less severe disease, as we know that at least five cases deceased but none of them were part of this case-control study. We also suspect some selection bias in the recruitment and selection of controls. We recruited participants through RIVM social media channels to sign up for the study; this might have reached a specific highly educated, and health- and research-minded population, which is not representative for the total population in the Netherlands. This may explain the significantly higher education level among parents of controls.

Due to the small numbers we could not conduct a thorough multivariable analysis and correct for possible confounders such as household size, education level and co-morbidities. Another limitation is that the risk factors in this study were only identified by anamnesis of the parents, and not proven by any microbiological analysis.

Conclusion

This study showed that the risk of iGAS in children 6 months to 5 years is associated with prior varicella zoster infection and exposure to GAS like illnesses in the social environment, in particular scarlet fever. General practitioners should be aware of these pediatric iGAS risk factors, especially in settings of high varicella zoster and/or scarlet fever circulation. The results of this study are relevant for informing policies on varicella zoster vaccination and distribution of post-exposure prophylaxis

It is made available under a CC-BY-NC-ND 4.0 International license .

among contacts of iGAS cases to prevent invasive disease, especially in outbreak settings where

multiple pathogens are co-circulating and increasing the risk of developing iGAS.

It is made available under a CC-BY-NC-ND 4.0 International license .

Characteristics		Cases (N	=18)	Controls (N=103)		
		n	%	n	%	
Sex	Male	10	56.0	55	53.0	
Year of birth	2017	1	5.6	7	6.8	
	2018	1	5.6	7	6.8	
	2019	3	17.0	15	15.0	
	2020	1	5.6	8	7.8	
	2021	6	33.0	34	33.0	
	2022	6	33.0	32	31.0	

Table 1. Matching characteristics of cases and controls.

It is made available under a CC-BY-NC-ND 4.0 International license .

Table 2. Univariable analysis of potential risk factors for developing iGAS, four weeks prior to disease

onset, cases (N = 18) compared to controls (N = 103), Netherlands, February-May 2023.

Risk factors	Cases (N=18)		Controls (N=103)		Univariate			
	n	%	n	%	OR	95% CI		
Infectious disease symptoms								
Cough	9	50.0	64	62.0	0.6	0.2-1.7		
Runny nose	10	56.0	79	77.0	0.4	0.1-1.0		
Shortness of breath	4	22.0	7	6.8	3.6	0.9-14.0		
Sore throat	5	28.0	15	15.0	2.5	0.7-9.0		
Respiratory infection ¹	14	78.0	87	85.0	0.6	0.2-2.2		
Impetigo	1	5.6	0	0.0	-	-		
Pharyngitis	3	16.7	4	3.9	4.7	0.9-25.0		
Scarlet fever	0	0.0	1	1.0	-	-		
GAS like illness ²	4	22.0	4	3.9	8.5	1.5-49.0		
Varicella zoster (chickenpox)	2	11.0	1	1.0	12.0	1.1-139.0		
Fever	15	83.0	41	40.0	7.5	2.1-28.0		
Otitis media	2	11.1	10	9.7	1.1	0.2-5.8		
Pneumonia	2	11.0	1	1.0	7.3	0.7-81.0		
Scabies	0	0.0	0	0.0	-	-		
Wound inflammation	3	17.0	6	5.8	3.4	0.7-17.0		
Chronic illnesses								
Any chronic illness	4	22.0	14	14.0	1.7	0.5-5.7		
Asthma	1	5.6	2	1.9	2.8	0.3-31.0		
Diabetes	0	0.0	0	0.0	-	-		
Eczema	3	17.0	10	9.7	1.8	0.5-6.9		

It is made available under a CC-BY-NC-ND 4.0 International license .

Heart disease	0	0.0	2	1.9	-	-		
Immune deficiency	0	0.0	0	0.0	-	-		
Kidney disease	0	0.0	0	0.0	-	-		
Psoriasis	0	0.0	1	1.0	-	-		
Rheumatic arthritis	0	0.0	0	0.0	-	-		
Medication								
Any antibiotic use	3	16.7	5	4.9	5.1	0.8-32.1		
Household size ³								
1-3 persons	5	28.0	38	37.0				
4-5 persons	12	67.0	63	62.0	1.9	0.5-6.7		
>6 persons	1	5.6	1	1.0	8.3	0.4-180.0		
Education level parents ⁴								
Low	6	33.0	9	8.7	-	-		
Medium/high	11	61.0	93	90.0	0.1	0.0-0.5		
Other								
Attending daycare/school	15	83.0	74	73.0	1.8	0.5-7.0		

¹ Combination of following variables: runny nose or cough or shortness of breath or sore throat.

² Combination of following variables: scarlet fever or impetigo or pharyngitis.

⁴ Total household size; including case or control.

⁵ Low: no education, primary and/or secondary school. Medium/high: bachelor's or master's degree or PhD.

It is made available under a CC-BY-NC-ND 4.0 International license .

Table 3. Univariable analysis of GAS-like illnesses in the social environment, four weeks prior to

disease onset, cases (N = 18) compared to controls (N = 103), Netherlands, February-May 2023.

Risk factors		Cases (N=18)		Controls (N=103)		Univariate		
		n	%	n	%	OR	95% CI	
GAS-like illnesses present in the social environment								
Impetigo	Household	1	5.6	0	0.0	-	-	
	Social environment	3	18.0	4	4.4	7.2	1.0-54.0	
Pharyngitis	Household	4	22.0	9	8.7	3.0	0.7-12.0	
	Social environment	0	0.0	2	1.9	-	-	
Scarlet fever	Household	0	0.0	0	0.0	-	-	
	Social environment	3	17.0	1	1.0	24.0	2.2-257.0	
Any GAS like	Household	5	28.0	9	8.7	3.8	1.0-14.0	
illness ¹	Social environment	8	44.0	15	15.0	7.1	1.8-29.0	

¹Combination of following variables: scarlet fever or impetigo or pharyngitis.



Figure 1. Process from recruitment (February-May 2023) of cases and controls to final dataset for analysis.

It is made available under a CC-BY-NC-ND 4.0 International license .

Acknowledgements

The authors would like to thank all participating parents for contributing to this study, the Municipal Health Services in the Netherlands for their support in the data collection, the OSIRIS support team and the Infectieradar-team for using their platform to distribute questionnaires.

References

- Nelson GE, Pondo T, Toews KA, Farley MM, Lindegren ML, Lynfield R, et al. Epidemiology of Invasive Group A Streptococcal Infections in the United States, 2005-2012. Clin Infect Dis. 2016;63(4):478-486.
- Landelijke Coördinatie Infectieziektenbestrijding (LCI). Richtlijn Groep A streptokokken infectie. 2012. Cited 20 Feb 2023. Available from: <u>Groep A-streptokokkeninfectie | LCI</u> <u>richtlijnen (rivm.nl)</u>
- 3. De Gier B, Marchal N, De Beer-Schuurman I, Te Wierik M, Hooiveld M, ISIS-AR Study Group, et al. Increase in invasive group A streptococcal (Streptococcus pyogenes) infections (iGAS) in young children in the Netherlands, 2022. Euro Surveill. 2023 Jan;28(1)2200941.
- European Center for Disease prevention and Control (ECDC). Increase in Invasive Group A streptococcal infections among children in Europe, including fatalities. Press release 12 Dec 2022. Available from: <u>Increase in Invasive Group A streptococcal infections among children</u> in Europe, including fatalities (europa.eu)
- Guy R, Henderson KL, Coelho J, Hughes H, Mason EL, Gerver SM, et al. Increase in invasive group A streptococcal infection notifications, England, 2022. Euro Surveill. 2023;28(1):pii=2200942.
- Santé Publique France. Infection invasive à streptocoque du Groupe A (IISGA): point de situation au 6 décembre 2022. Saint-Maurice cedex: Santé Publique France; 2022. French.
 Available from: <u>Infection invasive à streptocoque du Groupe A (IISGA) : point de situation au 6 décembre 2022 (santepubliquefrance.fr)</u>
- Health Protection Surveillance Center (HPSC). Update on group A streptococcus. Dublin: HPSC; 2022. Availabe from: <u>News: Update on Group A streptococcus - Health Protection</u> <u>Surveillance Centre (hpsc.ie)</u>
- 8. Nygaard U, Hartlink UB, Munkstrup C, Nielsen AB, Schultz Dungu KH, Samso Schmidt L, et al. Invasive group A streptococcal infections in children and adolescents in Denmark during

medRxiv preprint doi: https://doi.org/10.1101/2024.11.13.24316742; this version posted November 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

2022-23 compared with 2016-17 to 2021-22: a nationwide, multicentre, population-based cohort study. The Lancet Child & Adolescent Health. Volume 8, Issue 2, 2024 Feb: 112-121.

- Valcarcel Salamanca B, Cyr PR, Emblem Bentdal Y, Viksmoen Watle S, Wester AL, Wikman Strand AM, et al. Increase in invasive group A streptococcal infections (iGAS) in children and older adults, Norway, 2022 to 2024. Euro Surveill. 2024;29(20):pii=2400242.
- Van Kempen EB, Bruijning-Verhagen PCJ, Borensztajn D, Vermont CL, Quaak MSW, Janson JA, et al. Increase in invasive group A streptococcal infections in children in the Netherlands, a survey among 7 hospitals in 2022. Pediatr Infect Dis J. 2023 Apr 1;42(4)e122-e124. Epub 2022 Dec 29.
- Imöhl M, Van der Linden M, Rinert RR, Ritter K. Invasive group A streptococcal disease and association with varicella in Germany, 1996-2009. FEMS Immunol Med Microbiol. 2011 Jun;62(1):101-109.
- 12. De Gier B, Vlaminckx BJM, Woudt SHS, Van Sorgge NM, Van Asten L. Associations between common respiratory viruses and invasive group A streptococcal infection: A time-series analysis. Influenza Other Respir Viruses. 2019 Sep;13(5):453-468.
- 13. Herrera AL, Huber VC, Chaussee MS. The association between invasive group A streptococcal diseases and viral respiratory tract infections. Front Microbiol. 2016;7:342
- 14. Cohen R, Pettoello-Mantovani M, Somekh E, Levy C. European Pediatric Societies Call for an Implementation of Regular Vaccination Programs to Contrast the Immunity Debt Associated to Coronavirus Disease-2019 Pandemic in Children. J Pediatr. 2022 Mar;242:260-261.e3.
- 15. R Studio Team. RStudio: Integrated Development for R. 2023. Boston.
- 16. De Gier B, Van de Kassteele J, Van Asten L, Schoffelen A, ISIS-AR study group, Hooiveld M, Te Wierik MJM, Van Sorge NM, De Melker HE. Attribution of invasive group A streptococcal infections to varicella and respiratory virus circulation, the Netherlands, 2010-2023. Medrxiv preprint, January 10, 2024.

- 17. Watts V, Balasegaram S, Brown CS, Mathew S, Mearkle R, Ready D, Saliba V, Lamagni T. Increased risk for invasive Group A *Streptococcus* Disease for household contacts of scarlet fever cases, England, 2011-2016. Emerg Infect Dis 2019 Mar; 25(3):529-537.
- 18. Van den Boogaard J, Hahné SJM, Te Wierik MJM, Knol MJ, Balasegaram S, De Gier B. Out-ofseason increase of puerperal fever with group A *Streptococcus* infections: a case-control study, Netherlands, July to August 2018. Euro Surveill. 2020 Okt 8;25(40).